|
A program proposed by the Generic Pharmaceutical Association to help the Food and Drug Administration manage drug shortages “is unlikely to harm competition” if implemented as described, the Federal Trade Commission said in an advisory opinion yesterday. As part of the Accelerated Recovery Initiative, drug makers would pool production information about shortage drugs. “Although the supply and output data to be collected is competitively sensitive, and markets for the drugs in the ARI are likely to be susceptible to collusion, GPhA has designed the program to safeguard competitively sensitive information, with the aim of helping FDA to address extensive and unprecedented supply disruptions that threaten patient care,” the advisory opinion states.
|
